ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 840

The CCL21/CCR7 Axis Drives Vascular, Inflammatory and Destructive Remodeling in Rheumatoid Arthritis

Katrien Van Raemdonck1,2, Karol Palasiewicz1,2, Sadiq Umar1,2 and Shiva Shahrara2, 1Jesse Brown VA Medical Center, Chicago, IL, 2Medicine, Division of Rheumatology, University of Illinois at Chicago, Chicago, IL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Animal models, chemokines, macrophages, osteoclastogenesis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: 3S080 ACR Abstract: Cytokines & Cell Trafficking (840–845)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

The synovial tissue of rheumatoid arthritis (RA) patients exhibits abundant expression of CCL21, produced excessively by RA fibroblasts and macrophages. While CCR7 mediates CCL21-driven T cell migration, we previously identified a novel angiogenic function of CCL21 in RA as well. We now reveal that in RA, macrophage expression of CCR7 is significantly increased, which further supports the importance of the CCL21/CCR7 pathway. In this study, we aim to determine the range of CCL21/CCR7 function and explore its activity on CCR7+ macrophages, contributing to the progression of inflammatory and destructive RA.

Methods:

Expression of CCR7 on healthy (NL) versus RA immune cells was examined by flow cytometry and quantitative PCR. To evaluate CCL21-stimulated myeloid cell behavior, we performed monocyte chemotaxis, osteoclastogenesis assays and Western blot analysis for signaling. We also defined macrophage polarization through flow cytometry and ELISA. Intra-articular adenoviral delivery of CCL21 in mice was used to evaluate and confirm the arthritic effects of CCL21 in vivo.

Results:

The percentage of double-positive CD14+CCR7+ is 2-fold higher in macrophages derived from RA compared to NL peripheral blood (NL: 19.38 ± 2.7 %; RA: 43.14 ± 2.2 %). We find that in vitro M1 polarized cells express higher levels of CCR7, which corroborates the high expression of CCR7 on macrophages isolated from RA synovial fluid. Confirming the clinical significance of CCL21/CCR7, monocyte chemotaxis induced by RA synovial fluid is considerably reduced in the presence of either anti-CCR7 or anti-CCL21 neutralizing antibody. Recombinant CCL21 stimulates RA monocyte chemotaxis dose-dependently, through CCR7 and activation of NFκB, ERK and MAPK p38 signaling. CCL21 also affects myeloid cell differentiation and polarization. We observed an increase of M1 polarized macrophages upon CCL21 stimulation. Additionally, CCL21 ligation to CCR7 promotes osteoclast formation. Accordingly, local expression of CCL21 induces joint swelling and osteoclastic bone erosion in wild type mice, but not in CCR7-deficient mice. Histological analysis demonstrates that F4/80+ cell numbers are elevated in CCL21-treated arthritic joints. iNOS expression in the joint is increased 36-fold by CCL21. Elevated intra-articular production of M1-associated inflammatory factors confirms that local CCL21 expression promotes macrophage polarization to an M1 phenotype. We also noted that TRAP+ osteoclast numbers are 10-fold higher in CCL21 arthritic mice compared to the placebo non-arthritic group.

Conclusion:

Our findings emphasize the diverse function of CCL21 and CCR7, increased even more by the pathogenic upregulation of CCR7 expression on RA macrophages. Given that CCL21/CCR7 activation potentiates RA joint inflammation, destruction and neovascularization, this pathway may be an attractive target for therapy.


Disclosure: K. Van Raemdonck, None; K. Palasiewicz, None; S. Umar, None; S. Shahrara, None.

To cite this abstract in AMA style:

Van Raemdonck K, Palasiewicz K, Umar S, Shahrara S. The CCL21/CCR7 Axis Drives Vascular, Inflammatory and Destructive Remodeling in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-ccl21-ccr7-axis-drives-vascular-inflammatory-and-destructive-remodeling-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-ccl21-ccr7-axis-drives-vascular-inflammatory-and-destructive-remodeling-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology